Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day

Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day

Fiona Craig

Tue, September 1, 2026 at 3:56 PM GMT+3 2 min read

• GUTS -0.20%

Fractyl Health (NASDAQ:GUTS) shares rose 2.8% in pre-market trading ahead of the company's Virtual Commercial Strategy Day, scheduled for 11:00 AM ET on Tuesday.

Management is expected to provide details on the planned commercial strategy and market opportunity for Revita®, the company's procedural therapy being developed for weight maintenance following discontinuation of GLP-1 treatments.

The event follows the release of clinical data from Fractyl Health's REMAIN-1 Midpoint Cohort and comes ahead of additional regulatory and clinical milestones expected later in 2026.

REMAIN-1 data show difference in weight maintenance

In the REMAIN-1 Midpoint Cohort, patients receiving complete duodenal ablation with Revita maintained approximately 84% of their previous GLP-1-induced weight loss, compared with around 46% among patients receiving the sham procedure.

Fractyl Health is expected to discuss those findings as part of Tuesday's presentation on Revita's potential commercial positioning.

The company estimates that approximately 30 million adults in the United States currently use GLP-1 therapies. Revita is being developed as a one-time procedure for patients discontinuing those treatments.

The clinical results and estimates remain subject to further evaluation, and the potential commercial opportunity will depend on factors including subsequent trial results and regulatory decisions.

Analysts issue differing ratings on Fractyl Health

Bank of America Securities issued a "Buy" rating on Fractyl Health in mid-August, while Morgan Stanley maintained a "Hold" rating around the same period.

These analyst ratings represent the respective firms' assessments and do not indicate future share-price performance.

Fractyl Health is also approaching a pivotal clinical readout expected in early fourth-quarter 2026. The company is targeting a potential FDA De Novo marketing application in late fourth-quarter 2026, subject to the outcome of its development and regulatory programme.

Shares advance ahead of company presentation

Fractyl Health's pre-market increase came as the broader U.S. equity market traded lower, with the S&P 500 and Dow Jones declining and the Nasdaq also moving lower.

The information provided does not establish the extent to which Tuesday's scheduled investor event or previous clinical and analyst developments contributed to the 2.8% share-price increase.

Investors will receive further information on Fractyl Health's commercial plans for Revita during Tuesday's Virtual Commercial Strategy Day, while the company continues toward its anticipated clinical and regulatory milestones later this year.

Fractyl Health stock price